Synthesis, structure and antibacterial activity of potent DNA gyrase inhibitors: N'-benzoyl-3-(4-bromophenyl)-1H-pyrazole-5-carbohydrazide derivatives. 2013

Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.

A total of 19 novel (3a-3s) N'-benzoyl-3-(4-bromophenyl)-1H-pyrazole-5-carbohydrazide analogs were designed, synthesized, and evaluated for biological activities as potential DNA gyrase inhibitors. The results showed that compound 3k can strongly inhibit Staphylococcus aureus DNA gyrase and Bacillus subtilis DNA gyrase (with IC50 of 0.15 µg/mL and 0.25 µg/mL, respectively). Structure-activity relationships were also discussed base on the biological and docking simulation results.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II

Related Publications

Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
November 2013, Acta crystallographica. Section E, Structure reports online,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
February 2014, Organic & biomolecular chemistry,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
July 2004, Journal of medicinal chemistry,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
January 2005, Farmaco (Societa chimica italiana : 1989),
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
December 2011, European journal of medicinal chemistry,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
May 2023, ACS omega,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
August 2009, Acta crystallographica. Section E, Structure reports online,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
November 2011, Medicinal chemistry (Shariqah (United Arab Emirates)),
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
April 2021, European journal of medicinal chemistry,
Juan Sun, and Peng-Cheng Lv, and Yong Yin, and Rong-Ju Yuan, and Jian Ma, and Hai-Liang Zhu
July 2014, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!